Skip to main content

Cue Biopharma Inc

For the period ended Jun 30, 2024. Filed Aug 14, 2024.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 14, 2024

CUE$20.14+7.5%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Balance Sheets

June 30,2024December 31,2023
ASSETS
Current assets:
Cash and cash equivalents$30,029$48,514
Accounts receivable1,8471,698
Prepaid expenses and other current assets2,0241,242
Total current assets33,90051,454
Property and equipment, net667795
Operating lease right-of-use assets4,8106,323
Deposits2,6902,690
Restricted cash151151
Other long-term assets111117
Total assets$42,329$61,530
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable$3,906$3,501
Accrued expenses4,5624,137
Research and development contract liability, current portion9762,112
Operating lease liabilities, current3,0523,368
Current portion of long-term debt, net3,9633,963
Total current liabilities16,45917,081
Operating lease liabilities, non-current1,9623,162
Long-term debt, net2,2864,202
Total liabilities$20,707$24,445
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized and 0 shares issued and outstanding at June 30, 2024 and December 31, 2023——
Common stock, $0.001 par value; 100,000,000 shares authorized; 48,643,316 and 47,215,116 shares issued and outstanding, at June 30, 2024 and December 31, 2023, respectively4847
Additional paid in capital345,282338,228
Accumulated deficit(323,708)(301,190)
Total stockholders’ equity21,62237,085
Total liabilities and stockholders’ equity$42,329$61,530
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.